Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18950742 | 0.78 | CHRM2 (0.31) | SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL18361745 | 0.76 | — | — | |
| SCHEMBL21276777 | 0.76 | SLC6A2 (0.31) | SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL15479670 | 0.76 | — | — | |
| SCHEMBL16364822 | 0.76 | — | — | |
| SCHEMBL17051491 | 0.72 | — | — | |
| SCHEMBL19979184 | 0.71 | SLC6A2 (0.32) | SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL20748213 | 0.70 | — | — | |
| SCHEMBL30613663 | 0.70 | — | — | |
| SCHEMBL4291776 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233156-B2 | 9-membered fused ring derivative | SHIONOGI & CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-10189843-B2 | Fused pyrazole derivative having autotaxin inhibitory activity | THE UNIVERSITY OF TOKYO (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | SLC6A2 1864/4885ADRA1A 1179/4885HTR2B 2951/4885 |
| US-10189843-B2 | Fused pyrazole derivative having autotaxin inhibitory activity | ENPP2, PRTN3, TPX2 | SLC6A2 4578/4885ADRA1A 1353/4885HTR2B 2321/4885 |
| US-10233156-B2 | 9-membered fused ring derivative | AGTR2, ACSS2, ACSL3 | SLC6A2 1663/4885ADRA1A 1291/4885HTR2B 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.